Logo image of IMTX

IMMATICS NV (IMTX) Stock Fundamental Analysis

NASDAQ:IMTX - Nasdaq - NL0015285941 - Common Stock - Currency: USD

6.1  -0.32 (-4.98%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMTX. IMTX was compared to 550 industry peers in the Biotechnology industry. IMTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IMTX had negative earnings in the past year.
In the past year IMTX has reported a negative cash flow from operations.
In multiple years IMTX reported negative net income over the last 5 years.
In multiple years IMTX reported negative operating cash flow during the last 5 years.
IMTX Yearly Net Income VS EBIT VS OCF VS FCFIMTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

IMTX has a Return On Assets of -3.36%. This is amongst the best in the industry. IMTX outperforms 88.36% of its industry peers.
IMTX has a better Return On Equity (-4.02%) than 90.00% of its industry peers.
Industry RankSector Rank
ROA -3.36%
ROE -4.02%
ROIC N/A
ROA(3y)-2.39%
ROA(5y)-28.72%
ROE(3y)-7.75%
ROE(5y)-130.43%
ROIC(3y)N/A
ROIC(5y)N/A
IMTX Yearly ROA, ROE, ROICIMTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMTX Yearly Profit, Operating, Gross MarginsIMTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

IMTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMTX has more shares outstanding
The number of shares outstanding for IMTX has been increased compared to 5 years ago.
Compared to 1 year ago, IMTX has an improved debt to assets ratio.
IMTX Yearly Shares OutstandingIMTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
IMTX Yearly Total Debt VS Total AssetsIMTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

IMTX has an Altman-Z score of 3.34. This indicates that IMTX is financially healthy and has little risk of bankruptcy at the moment.
IMTX has a better Altman-Z score (3.34) than 73.82% of its industry peers.
IMTX has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
IMTX has a Debt to Equity ratio of 0.03. This is in the lower half of the industry: IMTX underperforms 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 3.34
ROIC/WACCN/A
WACC7.09%
IMTX Yearly LT Debt VS Equity VS FCFIMTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

IMTX has a Current Ratio of 10.28. This indicates that IMTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.28, IMTX is in the better half of the industry, outperforming 79.82% of the companies in the same industry.
IMTX has a Quick Ratio of 10.28. This indicates that IMTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IMTX (10.28) is better than 79.82% of its industry peers.
Industry RankSector Rank
Current Ratio 10.28
Quick Ratio 10.28
IMTX Yearly Current Assets VS Current LiabilitesIMTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 84.54% over the past year.
The Revenue has grown by 93.45% in the past year. This is a very strong growth!
Measured over the past years, IMTX shows a very strong growth in Revenue. The Revenue has been growing by 53.31% on average per year.
EPS 1Y (TTM)84.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
Revenue 1Y (TTM)93.45%
Revenue growth 3Y64.83%
Revenue growth 5Y53.31%
Sales Q2Q%-38.61%

3.2 Future

Based on estimates for the next years, IMTX will show a very negative growth in Earnings Per Share. The EPS will decrease by -55.90% on average per year.
IMTX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.70% yearly.
EPS Next Y-954.54%
EPS Next 2Y-239.41%
EPS Next 3Y-124.62%
EPS Next 5Y-55.9%
Revenue Next Year-44.96%
Revenue Next 2Y-25.1%
Revenue Next 3Y-10.27%
Revenue Next 5Y13.7%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IMTX Yearly Revenue VS EstimatesIMTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
IMTX Yearly EPS VS EstimatesIMTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMTX Price Earnings VS Forward Price EarningsIMTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMTX Per share dataIMTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A cheap valuation may be justified as IMTX's earnings are expected to decrease with -124.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-239.41%
EPS Next 3Y-124.62%

More info and screens

0

5. Dividend

5.1 Amount

IMTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMATICS NV

NASDAQ:IMTX (8/13/2025, 8:16:02 PM)

6.1

-0.32 (-4.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12
Earnings (Next)11-17 2025-11-17
Inst Owners67.75%
Inst Owner Change-0.45%
Ins Owners4.66%
Ins Owner ChangeN/A
Market Cap741.46M
Analysts87.14
Price Target14.72 (141.31%)
Short Float %4.79%
Short Ratio6.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)113.62%
Min EPS beat(2)0.45%
Max EPS beat(2)226.79%
EPS beat(4)4
Avg EPS beat(4)84.55%
Min EPS beat(4)0.45%
Max EPS beat(4)226.79%
EPS beat(8)7
Avg EPS beat(8)52.34%
EPS beat(12)9
Avg EPS beat(12)31.36%
EPS beat(16)9
Avg EPS beat(16)4.66%
Revenue beat(2)2
Avg Revenue beat(2)147.64%
Min Revenue beat(2)30.5%
Max Revenue beat(2)264.77%
Revenue beat(4)4
Avg Revenue beat(4)134.3%
Min Revenue beat(4)30.5%
Max Revenue beat(4)264.77%
Revenue beat(8)7
Avg Revenue beat(8)68.31%
Revenue beat(12)9
Avg Revenue beat(12)49.51%
Revenue beat(16)9
Avg Revenue beat(16)25.92%
PT rev (1m)0%
PT rev (3m)-5.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.43
P/FCF N/A
P/OCF N/A
P/B 1.19
P/tB 1.19
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-1.66
Fwd EYN/A
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS1.38
BVpS5.12
TBVpS5.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.36%
ROE -4.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.39%
ROA(5y)-28.72%
ROE(3y)-7.75%
ROE(5y)-130.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.52%
Cap/Sales 7.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.28
Quick Ratio 10.28
Altman-Z 3.34
F-Score4
WACC7.09%
ROIC/WACCN/A
Cap/Depr(3y)217.11%
Cap/Depr(5y)185.86%
Cap/Sales(3y)23.83%
Cap/Sales(5y)22.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
EPS Next Y-954.54%
EPS Next 2Y-239.41%
EPS Next 3Y-124.62%
EPS Next 5Y-55.9%
Revenue 1Y (TTM)93.45%
Revenue growth 3Y64.83%
Revenue growth 5Y53.31%
Sales Q2Q%-38.61%
Revenue Next Year-44.96%
Revenue Next 2Y-25.1%
Revenue Next 3Y-10.27%
Revenue Next 5Y13.7%
EBIT growth 1Y31.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.5%
EBIT Next 3Y-52.74%
EBIT Next 5Y-33.65%
FCF growth 1Y-304.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-388.17%
OCF growth 3YN/A
OCF growth 5YN/A